Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Trial Profile

Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Busulfan (Primary) ; Fludarabine (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Aug 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 08 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 02 Sep 2010 Planned end date changed from 1 Sep 2011 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top